Study Notes on Pulmonary Embolism

Introduction to Pulmonary Embolism

Pulmonary embolism (PE) is a critical condition affecting the respiratory system, often leading to severe complications or mortality if not diagnosed and treated promptly.

Understanding Pulmonary Embolism

Pulmonary embolism falls under the umbrella term venous thromboembolism (VTE), which includes conditions caused by blood clots within veins. The most common forms of VTE are:

  1. Deep Vein Thrombosis (DVT): Blood clots that typically develop in the lower limbs, often located in the calves.

  2. Pulmonary Embolism (PE): Blood clots that travel to the lungs, often originating from DVTs that have dislodged and moved through the right side of the heart before obstructing pulmonary arteries.

Causes of VTE

The historical framework for understanding why patients develop VTE is encapsulated by Virchow's Triad, which consists of three components:

  1. Endothelial Injury: Damage to the blood vessel walls, due to factors such as trauma or surgical procedures, that exposes blood to tissue factor, thereby activating the coagulation cascade.

  2. Venous Stasis: Alterations in blood flow caused by conditions such as prolonged immobility, illness, or long-distance travel may lead to insufficient clearance of clotting factors, promoting thrombus formation.

  3. Hypercoagulable State: Changes in blood composition that either arise from genetic predispositions or from acquired conditions, such as malignancy, pregnancy, or inflammation.

Importance of Understanding PE

PE is significant due to its prevalence and its potential for rapid mortality. Approximately 17,000 Australians are diagnosed with PE each year. Despite advances in treatment, mortality rates remain high, especially in high-risk patients, up to 30% in-hospital mortality. Survivors may experience long-term complications, such as persistent symptoms and chronic thromboembolic pulmonary hypertension (CTEPH), which is associated with poor prognosis. Furthermore, PE can be difficult to diagnose due to nonspecific symptoms, making awareness crucial.

Pathophysiology of PE

PE impacts both the lungs and the heart:

  1. Lung Effects: Normally, ventilation (airflow) is matched with perfusion (blood flow). In PE, obstruction of pulmonary vessels leads to areas of the lung being ventilated but not perfused, resulting in increased physiological dead space and significant ventilation-perfusion (V/Q) mismatch, leading to hypoxia.

  2. Right Ventricular Effects: The obstruction increases pulmonary vascular resistance, overloading the right ventricle, which is not designed to pump against elevated pressures. The right ventricle dilates, and as it loses contractile efficiency, it causes decreased cardiac output by insufficient blood flow to the left ventricle. This results in coronary blood flow reduction and ultimately ischemia of the right ventricle, creating a catastrophic cycle leading to right ventricular failure.

Clinical Presentation

A case study illustrates the typical presentation of a PE involving a 36-year-old female who exhibited symptoms of left-sided pleuritic chest pain and progressive dyspnea on exertion. Her symptoms began following an upper respiratory infection and subsequent confirmation of a COVID-19 infection. Noteworthy negatives include the absence of abdominal pain, dysuria, and recent travel or surgical history, as well as no lower limb symptoms.

Common Symptoms of PE

Symptoms of pulmonary embolism are often nonspecific but some typical presentations include:

  • Sudden onset pleuritic chest pain: chest pain triggered by inspiration.

  • Dyspnea: Shortness of breath, although young patients may present with less dyspnea due to higher cardiopulmonary reserve.

  • Dizziness and lightheadedness: These may occur due to decreased cardiac output.

  • Syncope: In severe cases, patients can present with fainting spells.

  • Leg Symptoms: Inquiry about leg pain or asymmetrical swelling is crucial, as many PEs originate from DVTs.

  • Hemoptysis: This is typically indicative of a pulmonary infarction rather than typical PE without infarction.

Patient History

In the discussed case, the patient's relevant past medical history includes:

  • Polycystic ovarian syndrome (menorrhagia issues)

  • High cholesterol

  • Gestational diabetes

  • Hypothyroidism

  • No previous VTE history

  • Current use of combined oral contraceptive pills for menorrhagia.

Risk Factors for VTE

Crucial risk factors for venous thromboembolism include:

  1. Personal history of VTE

  2. Family history of VTE (potential genetic factors)

  3. Malignancies (especially abdominal, lung, and certain brain cancers)

  4. Hormone therapy, especially estrogen-based contraceptives

  5. Chronic inflammatory diseases

  6. Recent surgical procedures

  7. Immobility (including prolonged travel)

  8. Obesity

In our patient's case, the identified VTE risk factors included recent COVID-19 infection and the combined oral contraceptive pill, which increases thrombotic event risks, particularly when the patient is less mobile due to illness.

Physical Examination

Upon examination, the patient presented with:

  • Normal blood pressure; tachycardia at 120 bpm; increased respiratory rate; normal oxygen saturation at 99% on room air; afebrile.

  • The patient appeared slightly uncomfortable due to chest pain, but normal capillary refill time and auscultation showed normal heart sounds with clear lung fields.

  • No signs of DVT were observed in either limb; vital signs were generally unremarkable except for tachycardia.

Examination Findings

Common findings in PE examination include:

  • Unremarkable or nonspecific vital signs except for possible tachycardia and tachypnea.

  • Occasionally, low-grade fever may present.

  • Potential symptoms of DVT, such as unilateral leg swelling and tenderness when observed.

  • On auscultation, pleural rub may be heard; in severe scenarios, signs of heart failure or pulmonary hypertension may emerge, including elevated jugular venous pressure and hypotension.

Differential Diagnosis

Given that PE symptoms are nonspecific, differential diagnosis for chest pain must include:

  • Sinister causes (to be ruled out): acute myocardial infarction, aortic dissection, pneumothorax.

  • Other causes of chest pain such as gastrointestinal and musculoskeletal origins should also be considered.

Initial Investigations

When encountering a patient with suspected PE, the initial investigations can be categorized into:

  1. Blood Tests: Conduct a full blood count, EUC (electrolytes, urea, and creatinine), liver function tests, C-reactive protein (CRP), and troponin to assess for myocardial infarction (MI) risk. D-dimer is crucial as a rule-out test for PE.

  2. Bedside Tests: Include an electrocardiogram (ECG) for cardiac assessment, and urinalysis may provide additional clues.

  3. Imaging: Begin with a chest X-ray to evaluate for alternative causes of chest pain such as pneumonia or pneumothorax.

D-dimer Test

The D-dimer test is significant in ruling out blood clots; it measures a fibrin degradation product within the bloodstream. Elevated levels may arise from various causes, making it crucial for all clinicians to note:

  • Normal D-dimer values are usually < 0.5 μg/mL and may change based on age; for individuals ≥50 years, normal values adjust to 0.01 μg/mL times their age (e.g., for an 80-year-old, the value would be < 0.8 μg/mL).

In our patient's case, blood tests showed:

  • EUC and renal function were normal.

  • Full blood count was within normal range.

  • CRP was elevated at 96 due to COVID-19 infection.

  • Coagulation profile was normal, and troponin was negative.

ECG Findings

In the context of PE, the most common ECG finding is sinus tachycardia. Although the S1Q3T3 pattern is notable for exams, it rarely appears in practice.

Chest X-ray Assessment

The chest X-ray for the patient was unremarkable, serving as a non-diagnostic step before confirming PE through deeper imaging studies.

Diagnostic Imaging for PE

The definitive imaging modality for confirming PE is CT pulmonary angiogram (CTPA), where contrast is injected and images are taken to visualize pulmonary arteries for clots. CTPA has advantages such as 24/7 availability allowing for immediate diagnostics and the ability to assess for other pathologies. Alternative imaging includes ventilation-perfusion (V/Q) scan, although its feasibility diminishes during after-hours.

Risk Assessment and Wells Criteria

In making the decision to perform imaging, risk stratification tools such as the Wells Criteria help clinicians gauge the likelihood of PE. For our patient, the Wells score was computed at 4.5, classifying her in the moderate risk category. A higher score indicates a greater likelihood of PE, which necessitates further confirmation via CTPA.

Management of Pulmonary Embolism

Upon diagnosis of PE, the main focus is initiating therapeutic anticoagulation to manage the condition. This can begin even prior to definitive imaging if a high suspicion of PE exists.

Initial Therapeutic Anticoagulation

  • Administer low molecular weight heparin (such as subcutaneous Clexane) or IV heparin based on renal function and condition stability of the patient.

Risk Stratification for Mortality Prediction

PE patients are categorized based on short-term mortality risk into:

  1. High Risk: Demonstrating hemodynamic instability (drop in BP or cardiac arrest).

  2. Intermediate Risk: Divided into Intermediate High (with both imaging and clinical evidence of right heart dysfunction) and Intermediate Low (showing only one of the indicators).

  3. Low Risk: No hemodynamic instability or evidence of right heart dysfunction.

Advanced Therapeutic Options

For intermediate to high-risk patients, multidisciplinary teams may consider advanced therapies. Such options include:

  • Systemic Thrombolysis: Administration of clot-busting drugs with notable bleeding risks.

  • Catheter-directed therapies: Procedures to directly lyse clots or remove them through thrombectomy.

  • Surgical Embolectomy: In emergency cases presenting with significant risk and failure.

Supportive Management

Besides anticoagulation, supportive treatment is essential: medications for pain management and oxygen therapy for hypoxemic patients.

Disposition Planning

Upon determining risk stratification, management dictates whether the patient can be discharged or requires admission. Follow-up protocols should assess for complications and potential residual symptoms.

Case Follow-up Plan

In our patient's case, she was diagnosed with intermediate low risk PE related to COVID-19, treated with therapeutic anticoagulation and analgesics, and monitored before transitioning to an oral anticoagulant upon stabilization. Follow-up was planned for three months post-discharge.

Long-Term Management

It is crucial to evaluate whether PE was provoked (with clear transient risk factors) or unprovoked (no obvious trigger).

  • Provoked PE typically requires 3-6 months of anticoagulation before cessation, while Unprovoked PE often necessitates lifelong therapy, potentially switching to prophylactic doses afterward.

  • VTE Prevention Strategies include advising patients on maintaining mobility during long travels, staying hydrated, and using compression stockings when necessary.

Key Takeaways

  1. PE Consideration: Always consider PE in differential diagnosis for patients with chest pain and shortness of breath.

  2. Judicious Use of Scans: Only employ imaging where clinical suspicion supports the likelihood of PE; misapplication can lead to unnecessary radiation exposure and healthcare costs.

  3. Timely Anticoagulation: Initiating anticoagulation promptly can be crucial in improving patient outcomes, sometimes even before confirmation through imaging.

In summary, understanding the complexities of pulmonary embolisms, including risk factors, diagnosis, and management strategies, is essential in effectively treating patients while minimizing potential risks and complications.